Association of prolactin with all-cause and cardiovascular mortality among patients with type 2 diabetes: a real-world study
An erratum to this article was published (Eur J Prev Cardiol, 10 Oct 2023 ↗)
Authors' conclusion
A positive association between baseline PRL and mortality was observed among patients with type 2 diabetes.
Study context
- Population
- Patients with T2DM with ≥2 prolactin measurements within 2 years of first inpatient diagnosis
- Participants
- 10,907 patients
- Exposure
- Baseline serum prolactin (PRL) levels
- Outcome
- All-cause and CV mortality
- Follow-up
- Mean 5.34 years
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Each group vs <100 mIU/LAdjusted hazard ratio (95% CI)
100-199 mIU/Lall-cause mortality
1.10(0.90–1.36)
200-299 mIU/Lall-cause mortality
1.35(1.11–1.67)
≥300 mIU/Lall-cause mortality
1.49(1.18–1.84)
100-199 mIU/LCV mortality
1.24(0.86–1.81)
200-299 mIU/LCV mortality
1.71(1.14–2.62)
≥300 mIU/LCV mortality
2.42(1.55–3.78)
- Deaths
- 863
- CV deaths
- 274
Observational data: associations, not effects.
Further findings
Mortality by mean PRL as exposure
- Positive associations also found with mean PRL
Subgroups by baseline characteristics
- Associations consistent across baseline characteristics
Sensitivity analyses excluding baseline subclinical/clinical hypothyroidism and deaths within first 6 months
- Similar results
Original publication
Association of prolactin with all-cause and cardiovascular mortality among patients with type 2 diabetes: a real-world study. Eur J Prev Cardiol. Published 12 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →